Terumo Corporation (TSE: 4543) announced today that it has completed its acquisition of certain assets owned by Abbott and St. Jude Medical on Jan. 20, 2017 (North American Central Standard Time). Terumo has acquired the Angio-Seal™ and FemoSeal™ vascular closure product lines and Kalila Medical, Inc., a company developing next-generation access technologies, the first being the Vado™ Steerable Sheath, used in cardiac electrophysiology procedures.
The acquired assets become part of Terumo Interventional Systems, a division of Terumo Corporation. By building on Terumo's existing infrastructure and competencies, the acquisition will enable Terumo to maximize the value of the acquired businesses and contribute to supporting safe and efficient interventional procedures.
The financial impact will be included on a consolidated basis, starting with the fourth quarter of the fiscal year ending March 31, 2017. The impact of the acquisition on Terumo's business performance is being examined. Further details regarding the impact of the acquisition will be disclosed as needed, once the analysis is completed.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over US$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.